Enlivex Therapeutics (ENLV) News Today → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Free ENLV Stock Alerts $1.40 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 2:20 AM | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Shares Down 0.7% April 29, 2024 | finance.yahoo.comEnlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsApril 22, 2024 | finance.yahoo.comEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisApril 18, 2024 | msn.comYet Another Biotech Stock Has Found Success During Tuesday's SessionApril 17, 2024 | msn.comEnlivex Therapeutics (ENLV) Price Target Decreased by 41.67% to 7.14April 16, 2024 | finance.yahoo.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 16, 2024 | globenewswire.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 13, 2024 | stockhouse.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With SepsisApril 12, 2024 | marketbeat.comEnlivex Therapeutics (NASDAQ:ENLV) Price Target Cut to $7.00 by Analysts at HC WainwrightHC Wainwright dropped their price objective on shares of Enlivex Therapeutics from $12.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday.April 11, 2024 | finance.yahoo.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | globenewswire.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | msn.comNasdaq Gains Over 50 Points; US Producer Prices Increase In MarchApril 11, 2024 | msn.comDow Dips 100 Points; CarMax Earnings Miss ViewsApril 11, 2024 | msn.comEnlivex stock plunges 50% on mixed results from sepsis studyApril 11, 2024 | globenewswire.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisApril 5, 2024 | msn.comENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023April 2, 2024 | marketbeat.comEnlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 15.4% in MarchEnlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 261,500 shares, an increase of 15.4% from the February 29th total of 226,600 shares. Based on an average trading volume of 108,300 shares, the days-to-cover ratio is currently 2.4 days.April 1, 2024 | marketbeat.comEnlivex Therapeutics (ENLV) Set to Announce Quarterly Earnings on TuesdayEnlivex Therapeutics (NASDAQ:ENLV) will be releasing earnings on Tuesday, April 2.March 22, 2024 | finanznachrichten.deEnlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 16, 2024 | marketbeat.comShort Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Expands By 51.2%Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 226,600 shares, a growth of 51.2% from the February 14th total of 149,900 shares. Based on an average trading volume of 104,700 shares, the days-to-cover ratio is presently 2.2 days.March 16, 2024 | finance.yahoo.comENLV Apr 2024 7.500 callMarch 9, 2024 | edition.cnn.comEnlivex Therapeutics Ltd.March 5, 2024 | marketbeat.comEnlivex Therapeutics (NASDAQ:ENLV) Trading Up 6.5%Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 6.5%February 26, 2024 | finance.yahoo.comEnlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee OsteoarthritisFebruary 22, 2024 | benzinga.comEnlivex Therapeutics Stock (NASDAQ:ENLV), Short Interest ReportFebruary 22, 2024 | finance.yahoo.comENLV May 2024 5.000 putFebruary 7, 2024 | finance.yahoo.comEnlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing MethodJanuary 17, 2024 | finance.yahoo.comEnlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisDecember 20, 2023 | finance.yahoo.comEnlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With SepsisDecember 16, 2023 | morningstar.comEnlivex Therapeutics Ltd ENLVDecember 12, 2023 | finance.yahoo.comIs Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?November 21, 2023 | finance.yahoo.comMediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial OfficerSeptember 11, 2023 | finance.yahoo.comEnlivex Announces Reprioritization Plan and Second Quarter 2023 Financial ResultsSeptember 7, 2023 | finance.yahoo.comEnlivex to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 2, 2023 | finance.yahoo.comEnlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19July 31, 2023 | finance.yahoo.comEnlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With SepsisJune 26, 2023 | finance.yahoo.comEnlivex Announces First Quarter 2023 Financial Results and Provides a Business UpdateJune 16, 2023 | benzinga.comThis Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To CancerJune 6, 2023 | finance.yahoo.comEnlivex to Present at the 2023 Jefferies Healthcare ConferenceMay 31, 2023 | finance.yahoo.comEnlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene TherapyMay 8, 2023 | finance.yahoo.comEnlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell TherapyApril 20, 2023 | marketwatch.comEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra(TM) in Patients Receiving CAR T-Cell TherapyApril 19, 2023 | finance.yahoo.comEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell TherapyApril 17, 2023 | finance.yahoo.comEnlivex Appoints Andrew Singer to its Board of DirectorsApril 14, 2023 | finance.yahoo.comAnalysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical TrialsApril 12, 2023 | finanznachrichten.deEnlivex Therapeutics Ltd.: Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid TumorsApril 11, 2023 | benzinga.comEnlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid TumorsApril 5, 2023 | msn.comHC Wainwright & Co. Reiterates Enlivex Therapeutics (ENLV) Buy RecommendationApril 5, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Enlivex (ENLV)April 4, 2023 | finanznachrichten.deEnlivex Therapeutics Ltd: Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address A once-in-a-century investment opportunity (Ad)It's an under-the-radar stock reshaping a projected $109 billion industry - And, I believe, has far more potential than the AI stocks most investors are focused on in the days ahead. To get its name and ticker symbol for free - just click here. ENLV Media Mentions By Week ENLV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENLV News Sentiment▼1.180.52▲Average Medical News Sentiment ENLV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENLV Articles This Week▼10▲ENLV Articles Average Week Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NRXP News Today THTX News Today APRE News Today ACST News Today ACXP News Today DARE News Today UBX News Today LPCN News Today BIOR News Today VIRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENLV) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceThe Presidential candidate you should REALLY be worried aboutStansberry ResearchProtect Your Bank Account Before It’s Too LateWeiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
